Jerome B. Durso's Insider Trades & SAST Disclosures
Jerome B. Durso's most recent trade in Altimmune Inc was a trade of 69,800 Stock Options (option to buy) done . Disclosure was reported to the exchange on Feb. 24, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Jerome B. Durso.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Altimmune Inc | Jerome B. Durso | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2025 | 69,800 | 69,800 | - | - | Stock Options (option to buy) | |
| Intercept Pharmaceuticals Inc | Jerome B. Durso | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jan 2023 | 82,700 | 82,700 | - | - | Option to Purchase Common Stock | |
| Intercept Pharmaceuticals Inc | Jerome B. Durso | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jan 2023 | 50,400 | 154,640 (0%) | 0% | 0 | Common Stock | |
| Intercept Pharmaceuticals Inc | Jerome B. Durso | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.37 per share. | 31 Dec 2022 | 7,083 | 104,240 (0%) | 0% | 12.4 | 87,617 | Common Stock |
| Intercept Pharmaceuticals Inc | Jerome B. Durso | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jan 2022 | 60,900 | 60,900 | - | - | Option to Purchase Common Stock | |
| Intercept Pharmaceuticals Inc | Jerome B. Durso | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jan 2022 | 35,700 | 111,323 (0%) | 0% | 0 | Common Stock | |
| Intercept Pharmaceuticals Inc | Jerome B. Durso | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 15.22 per share. | 01 Oct 2021 | 289 | 81,564 (0%) | 0% | 15.2 | 4,399 | Common Stock |
| Intercept Pharmaceuticals Inc | Jerome B. Durso | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.47 per share. | 01 Jul 2021 | 289 | 81,853 (0%) | 0% | 20.5 | 5,916 | Common Stock |
| Intercept Pharmaceuticals Inc | Jerome B. Durso | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.28 per share. | 01 Apr 2021 | 289 | 82,142 (0%) | 0% | 24.3 | 7,017 | Common Stock |
| Intercept Pharmaceuticals Inc | Jerome B. Durso | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.12 per share. | 23 Feb 2021 | 319 | 82,431 (0%) | 0% | 28.1 | 8,970 | Common Stock |
| Intercept Pharmaceuticals Inc | Jerome B. Durso | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jan 2021 | 72,000 | 72,000 | - | - | Option to Purchase Common Stock | |
| Intercept Pharmaceuticals Inc | Jerome B. Durso | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jan 2021 | 46,000 | 82,750 (0%) | 0% | 0 | Common Stock | |
| Intercept Pharmaceuticals Inc | Jerome B. Durso | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.47 per share. | 23 Nov 2020 | 319 | 38,784 (0%) | 0% | 35.5 | 11,315 | Common Stock |
| Intercept Pharmaceuticals Inc | Jerome B. Durso | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 42.08 per share. | 01 Oct 2020 | 289 | 39,103 (0%) | 0% | 42.1 | 12,161 | Common Stock |
| Intercept Pharmaceuticals Inc | Jerome B. Durso | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 48.21 per share. | 23 Aug 2020 | 319 | 39,392 (0%) | 0% | 48.2 | 15,379 | Common Stock |
| Intercept Pharmaceuticals Inc | Jerome B. Durso | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 46.52 per share. | 01 Jul 2020 | 289 | 39,711 (0%) | 0% | 46.5 | 13,444 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges